



Curriculum Vitae

Personal information **Antonius Ederveen**

Work experience

1. Employer: Medicines Evaluation Board
 - Start date: 082015
 - End date:
 - Position: Non_Clinical Assessor
 - Activities: Non_clinical assessment of Marketing Authorisation Applications for human medicinal products with focus on Pharmacology and Pharmacokinetics. Assessment of Scientific Advice (national and EMA).
 - Country: Netherlands
2. Employer: Pharmacokinetics, Pharmacodynamics & Drug Metabolism Department, Merck Sharp & Dohme (MSD)
 - Start date: 072011
 - End date: 012015
 - Position: Principal Scientist Clinical PK_PD
 - Activities: Providing clinical pharmacokinetic and pharmacodynamic (PK_PD) expertise support to project teams in early clinical phase (Phase I, SAD, MAD, DDI and bioequivalence studies) up to Proof of Concept
 - Country: Netherlands
3. Employer: Women's Health Department, Merck Sharp & Dohme
 - Start date: 112009
 - End date: 072011
 - Position: Head Breast Cancer / Menopause
 - Activities: Responsible for people management and strategic & translational scientific support for (pre)clinical drug development research on Breast Cancer / Menopause
 - Country: Netherlands
4. Employer: Women's Health Department, Schering Plough
 - Start date: 112007
 - End date: 042010
 - Position: Proof of Concept Team leader Selective Estrogens
 - Activities: Responsible for global project management of the Proof of Concept team, which activities comprised two Lead Optimisation projects for selecting clinical candidates, and three Early Development Compounds in clinical development up to Phase II clinic.
 - Country: Netherlands
5. Employer: Women's Health Department, Schering Plough
 - Start date: 112007
 - End date: 112009
 - Position: Head Osteoporosis / Hormone Dependent Disorders
 - Activities: Responsible for people management and strategic & translational scientific support for (pre)clinical drug development research on Osteoporosis and Hormone Dependent disorders (HDD)
 - Country: Netherlands
6. Employer: Dept. of Pharmacology, NV Organon
 - Start date: 081999
 - End date: 112007
 - Position: Head Osteoporosis / Hormone Therapy / Male Contraception
 - Activities: Responsible for people management (21-35 FTE) and general management, output and strategy of all scientific aspects related to osteoporosis, Hormone Therapy and Male Contraception research
 - Country: Netherlands
7. Employer: Dept. of Pharmacology, NV Organon
 - Start date: 041994
 - End date: 082003
 - Position: Lead Optimization Team Leader ER Selective Ligands
 - Activities: Leader of an Lead Optimisation Team, a multidisciplinary project, responsible for the selection and preclinical development of new clinical candidates
 - Country: Netherlands
8. Employer: Dept. of Endocrinology, NV Organon
 - Start date: 041990
 - End date: 081999
 - Position: Group Leader Hormone Therapy / Osteoporosis
 - Activities: Responsible for line management and for the development and performance of in vitro and in vivo assays for preclinical pharmacology research on osteoporosis and treatment of climacteric complaints
 - Country: Netherlands

Education and training

1. Subject: NV Organon, Schering Plough, MSD
 - Start date: 041990
 - End date:
 - Qualification: Post_Doctoral courses on Drug Development and Management
 - Organisation: Several courses to learn and/or improve skills with respect to drug

- development expertise, leading teams and Human Resource Management
 - Country: Netherlands
- 2. Subject: Radboud University Nijmegen; NV Organon
 - Start date: 1987
 - End date:
 - Qualification: Licensed animal researcher
 - Organisation: Licensed animal researcher legally allowed to design, approve and perform an animal experiment (Article 9 functionary within the Dutch Act on Animal Experimentation)
 - Country: Netherlands
- 3. Subject: Department of Biochemistry, Radboud University Nijmegen
 - Start date: 061985
 - End date: 061989
 - Qualification: PhD in Biochemistry
 - Organisation: In vitro / ex vivo biochemistry research, education of students and writing a thesis
 - Country: Netherlands
- 4. Subject: Radboud University Nijmegen
 - Start date: 091981
 - End date: 121981
 - Qualification: Radiological Health Expert (level 3)
 - Organisation: Working with dispersible radioactive substances, sealed sources and X-ray equipment; Managing/using a radionuclide laboratory
 - Country: Netherlands
- 5. Subject: Subfaculty Biology, Faculty of Science , Radboud University Nijmegen (previously Catholic University)
 - Start date: 091978
 - End date: 051985
 - Qualification: Master of Science (MSc) Biology
 - Organisation: Main directions: Endocrinology, Biochemistry & Experimental Dermatology
 - Country: Netherlands

Additional information

Publications

1. Zinken JF, Pasmooij AMG, Ederveen AGH, Hoekman J, Bloem LT. Environmental Risk Assessment In The EU Regulation Of Medicines For Human Use: An Analysis Of Stakeholder Perspectives On Its Current And Future Role. *Drug Discovery Today* 29(12), 104213-104228, 2024 (doi.org/10.1016/j.drudis.2024.104213, dec).
2. Krug AW, Vaddady P, Railkar RA, Musser BJ, Cote J, Ederveen AGH, Krefetz DG, DeNoia E, Free AL, Morrow L, Chakravarthy MV, Kauh E, Tatosian DA, Kothare PA. Leveraging a Clinical Phase Ib Proof_of_Concept Study for the GPR40 Agonist MK_8666 in Patients With Type 2 Diabetes for Model_Informed Phase II Dose Selection. *Clin Transl Sci* 10, 404_411, 2017 (doi:10.1111/cts.12479 Jul).
3. Knox CD, Kam PJ de, Azer K, Wong P, Ederveen AG, Shevell D, Morabito C, Meehan AG, Liu W, Reynders T, Deneff JF, Mitselos A, Jonathan D, Gutstein DE, Mitra K, Sun SY, Man_Chu Lo M, Cully D, Ali A. Discovery and Clinical Evaluation of MK_8150, A Novel Nitric Oxide Donor With a Unique Mechanism of Nitric Oxide Release. *J Am Heart Assoc.* 5(9), pii: e003493, 2016 Sept (doi: 10.1161/JAHA.116.003493, Aug).
4. Musser B, Bolognese J, Fayad G, Bhattacharyya J, Shentu Y, Ederveen A, Mixson L, Patel N. Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection. *Therapeutic Innovation and Regulatory Science* 49(3), 405 – 414, 2015.
5. Evers NM, Wang S, Berg JHJ van den, Houtman R, Melchers D, De Haan LHJ, Ederveen, AGH, Groten JP, Rietjens IMCM. Identification of coregulators involved in estrogen receptor subtype specific binding of the ER antagonists 4_hydroxytamoxifen and fulvestrant. *Chemico_Biological Interactions* 220, 222_230, 2014.
6. Evers NM, Berg JHJ van den, Wang S, Melchers D, Houtman R, De Haan LHJ, Ederveen AGH, Groten JP, Rietjens IMCM. Cell proliferation and modulation of interaction of estrogen receptors with coregulators induced by ERalpha and ERbeta agonists. *J Steroid Biochem Mol Biol* 143, 376 _ 385, 2014.
7. Amos_Landgraf JM, Heijmans J, Wielinga MCB, Dunkin E, Krentz KJ, Clipson L, Ederveen AG, Groothuis PG, Mosselman S, Muncan V, Hommes DW, Shedlovsky A, Dove WF, Brink GR van den. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. *PNAS* 111(46), 16514_16519, 2014.
8. Evers NM, Van der Klundert T, Van Aesch Y, Wang S, De Roos WK, Romano A, De Haan LH, Murk AJ, Ederveen AGH, Rietjens IMCM, Groten JP. Human T47D_ERbeta breast cancer cells with tetracycline_dependent ERbeta expression reflect ERalpha/ERbeta ratios in rat and human breast tissue. *Toxicology in Vitro* 27, 1753_1761, 2013 May.
9. Heijmans J, Wielinga M, Roosekrans S, Van Lidth de Jeude J, Roelofs J, Groothuis PG, Ederveen AGH, Jonge_Muller ESM de, Biemond I, Hardwick JC, Hommes DW, Muncan V, Brink GR van den. Estrogens Promote Tumorigenesis in a mouse model for colitis_associated cancer. *Gut* 63(2): 310_316 2014 (doi:10.1136/gutjnl_2012_304216, 2013 Feb).
10. Attia, DMA, Ederveen AGH. Opposing Roles Of ERalpha And ERbeta In The Genesis And Progression Of Adenocarcinoma In The Rat Ventral Prostate. *Prostate* 2012 72(9):1013_22 2012 Jun (doi: 10.1002/pros.21507).
11. Heijmans J, Muncan V, Jacobs RJ, Jonge_Muller ESM de, Graven L, Biemond I, Ederveen AG, Groothuis PG, Mosselman S, Hardwick JC, Hommes DW, Brink GR van den. Intestinal Tumorigenesis Is Not Affected By Progesterone Signaling In Rodent Models. *Plos One* 6(7) e22620: 1_7 2011 Jul (doi:10.1371/journal.pone.0022620).
12. Dassen H, Punyadeera C, Schulkens I, Delvoux B, Marchetti C, Kamps R, Klomp J, Dijcks F, De Goeij A, D'hooghe TM, Kyama CM, Ederveen A, Dunselman G, Groothuis P, Romano A. Estrogen_ Olfactomedin_4 Regulation By Estrogen In The Human Endometrium Requires Epidermal Growth Factor Signalling. *Am J Pathol* 177(5): 2495_508, 2010 Nov.
13. Greupink R, Sio CF, Ederveen A, Orsel J. Evaluation of a 99mTc_labeled AnnexinA5 Variant for Non_Invasive SPECT Imaging of Cell Death in Liver, Spleen and Prostate. *Pharmaceutical Res* 26(12): 2647_56, 2009 Dec.
14. Sniekers YH, van Osch GJVM, Ederveen AGH, Inzunza J, Gustafsson JA, van Leeuwen JPTM, Weinans H. Development Of Osteoarthritic Features In Estrogen Receptor Knockout Mice. *Osteoarthritis & Cartilage.* 17(10):1356_61, 2009 Oct.
15. Sinderen ML van, Boon WC, Ederveen AGH, Kloosterboer HJ, Simpson ER, Jones MEE. The Estrogenic Component Of Tibolone Reduces Adiposity In Female Aromatase Knockout (ArKO) Mice. *Menopause* 16(3): 582_588, 2009 May.
16. Punyadeera C, Kamps R, Defrere S, Dijcks F, de Goeij A, Ederveen A, Dunselman G, Groothuis P. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre_ and postmenopausal human endometrium. *J Steroid Biochem Mol Biol* 112(1_3):102_9, 2008 Nov.
17. Roa J, Vigo E, Castellano JM, Gaytan F, Navarro VM, Aguilar E, Dijcks FA, Ederveen AGH, Pinilla L, Noort PI van, Tena Sempere M. Follicle Stimulating Hormone Responses To Kisspeptin in The Female Rat at the Preovulatory Period: Modulation by Estrogen and Progesterone Receptors. *Endocrinology* 149(11):5783_90, 2008 Nov.
18. Jeanes HL, Tabor C, Black D, Ederveen A, Gray GA. Oestrogen_mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)agonist and unaffected by an ERbeta antagonist. *J Endocrinology* 197(3): 493_501, 2008 Jun.

19. Roa J, Vigo E, Castellano JM, Gaytan F, Navarro VM, Aguilar E, Dijcks FA, Ederveen AGH, Pinilla L, Noort PI van, Tena-Sempere M. Opposite Roles of Estrogen Receptor (ER) α and ER β in the Modulation of Luteinizing Hormone Responses to Kisspeptin in the Female Rat: Implications for the Generation of the Preovulatory Surge. *Endocrinology* 149(4): 1627-37, 2008 Apr.
20. Dassen H, Kamps R, Punyadeera C, Dijcks F, de Goeij A, Ederveen A, Dunselman G, Groothuis P. Hemoglobin expression in human endometrium. *Hum Reprod.* 23(3): 635-41, 2008 Mar.
21. Dassen H, Punyadeera C, Kamps R, Klomp J, Dunselman G, Dijcks F, de Goeij A, Ederveen A, Groothuis P. Progesterone regulation of implantation-related genes: new insights in the role of oestrogen. *Cell Mol Life Sci.* 64(7-8): 1009-32, 2007 Apr.
22. Blom MJ, Wassink MG, De Gooyer ME, Ederveen AGH, Kloosterboer HJ, Lange JL, Lambert JGD, Goos HJ. Metabolism of tibolone and its metabolites in uterine and vaginal tissue of rat and human origin. *J Steroid Biochem Mol Biol* 101(1):42-49, 2006 Sep.
23. Groothuis PG, De Gooyer ME, ten Kate J, Menheere PP, Dunselman GAJ, De Goeij AFPM, Verboost P, Ederveen AGH, Kloosterboer HJ. Tibolone and metabolites induce prolactin production in human endometrial stromal cells in vitro: evidence for cell-specific metabolism. *J Steroid Biochem Mol Biol* 100(4-5):152-160, 2006 Aug.
24. Ederveen A, Ellenbroek B. Whole animal pharmacology and the challenge to bridge the gap between animals and humans. *Editorial Drug Discovery Today: Technologies*, 3 (2): 113-114, 2006.
25. McNamara LM, Ederveen AGH, Lyons CG, Price C., Schaffler M.B, Weinans H, Prendergast PJ Strength of cancellous bone trabecular tissue from normal, ovariectomized, and drug-treated rats over the course of ageing. *Bone* 39(2): 392-400, 2006 Aug.
26. Waarsing JH, Day JS, Verhaar JAN, Ederveen AGH, Weinans H. Bone loss dynamics results in trabecular alignment in aging and ovariectomized rats. *J Orthop Res* 24(5):926-35, 2006 May.
27. Lees CJ, Ederveen AGH, Spanjers CPM, Clarkson TB. Effects of Tibolone on Bone Quality in Ovariectomized Monkeys. *Menopause* 12 (5): 613-618, 2005 Sept-Oct.
28. Punyadeera C, Dassen H, Klomp J, Dunselman G, Kamps R, Dijcks F, Ederveen A, de Goeij A, Groothuis P. Oestrogen-modulated gene expression in the human endometrium *Cell Mol Life Sci.* 62(2): 239-50, 2005 Jan.
29. Punyadeera C, Dunselman G, Marbaix E, Kamps R, Galant C, Nap A, de Goeij A, Ederveen A, Groothuis P. Triphasic pattern in the ex vivo response of human proliferative phase endometrium to oestrogens. *J Steroid Biochem Mol Biol* 92(3): 175-85, 2004 Oct.
30. Clarkson TB, Anthony MS, Cline JM, Lees CJ, Ederveen AGH. Multisystem Evaluations Of The Long-Term Effects Of Tibolone On Postmenopausal Monkeys. *Maturitas* 48 (Suppl 1): S24-S29, 2004 Aug.
31. Waarsing JH, Day JS, Van Der Linden JC, Ederveen AGH, Spanjers C, De Clerck N, Sasov A, Verhaar JAN, Weinans H. Detecting and tracking local changes in the tibiae of individual rats: A novel method to analyse longitudinal in vivo micro-CT data. *Bone* 34(1): 163-169, 2004 Jan.
32. Van Cromphaut SJ, Rummens K, Stockmans I, Van Herck E, Dijcks FA, Ederveen AGH, Carmeliet P, Verhaeghe J, Bouillon R, Carmeliet G. Intestinal Calcium Transporter Genes are Up-regulated by Estrogens and the Reproductive Cycle through Vitamin D Receptor Independent Mechanisms. *Journal of Bone & Mineral Research.* 18(10):1725-36, 2003 Oct.
33. Kloosterboer HJ. Ederveen AGH. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/_progestogen) treatments. *Journal of Steroid Biochemistry & Molecular Biology.* 83(1-5):157-65, 2002 Dec.
34. Kloosterboer HJ. Ederveen AGH. Tibolone - Its tissue-specificity and bone preserving effects. *Journal fur Menopause.* 9 (Suppl. 1): 16-19, 2002.
35. de Gooyer ME, Kleyn GT, Smits KC, Ederveen AGH, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. *Molecular & Cellular Endocrinology.* 183(1-2):55-62, 2001 Oct.
36. Ederveen AGH, Spanjers CP, Quaijtaal JH, Kloosterboer HJ. Effect of 16 months of treatment with tibolone on bone mass, turnover, and biomechanical quality in mature ovariectomized rats. *Journal of Bone & Mineral Research.* 16(9):1674-81, 2001 Sep.
37. Ederveen AGH, Kloosterboer HJ. Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor. *Journal of Bone & Mineral Research.* 16(9):1651-7, 2001 Sep.
38. Vandenput L, Ederveen AGH, Erben RG, Stahr K, Swinnen JV, Van Herck E, Verstuyf A, Boonen S, Bouillon R, Vanderschueren D. Testosterone prevents orchidectomy-induced bone loss in estrogen receptor- α knockout mice. *Biochemical & Biophysical Research Communications.* 285(1):70-6, 2001 Jul.
39. Blom MJ, Wassink MG, van Wijk F, Ederveen AG, Kloosterboer HJ, Verhoeven CH, Lambert JG, Goos HJ. Metabolism of norethisterone and norethisterone derivatives in rat uterus, vagina, and aorta. *Drug Metabolism & Disposition.* 29(7):976-82, 2001 Jul.
40. Blom MJ, Wassink MG, Kloosterboer HJ, Ederveen AG, Lambert JG, Goos HJ. Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment. *Drug Metabolism & Disposition.* 29(1):76-81, 2001 Jan.
41. Vanderschueren D, Boonen S, Ederveen AG, de Coster R, Van Herck E, Moermans K, Vandenput L, Verstuyf A, Bouillon R. Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. *Bone.* 27(5):611-7, 2000 Nov.
42. Rakover Y, Lu P, Briody JN, Tao C, Weiner E, Ederveen AG, Cowell CT, Ben-Shlomo I. Effects of delaying puberty on bone mineralization in female rats. *Human Reproduction.* 15(7):1457-61, 2000 Jul.
43. Cornelissen BP, van Weeren PR, Ederveen AG, Barneveld A. Influence of exercise on bone mineral density of immature cortical and trabecular bone of the equine metacarpus and proximal sesamoid bone. *Equine Veterinary Journal. Supplement.* (31):79-85, 1999 Nov.
44. Ederveen AG, Kloosterboer HJ. Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. *Journal of Bone & Mineral Research.* 14(11):1963-70, 1999 Nov.
45. van Bezooijen RL, Que I, Ederveen AG, Kloosterboer HJ, Papapoulos SE, Lowik CW. Plasma nitrate+nitrite levels are regulated by ovarian steroids but do not correlate with trabecular bone mineral density in rats. *Journal of Endocrinology.* 159(1):27-34, 1998 Oct.
46. Vanderschueren D, van Herck E, Nijs J, Ederveen AGH, De Coster R, Bouillon R. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. *Endocrinology.* 138(6):2301-7, 1997 Jun.
47. Most W, van der Wee-Pals L, Ederveen A, Papapoulos S, Lowik C. Ovariectomy and orchidectomy induce a transient increase in the osteoclastogenic potential of bone marrow cells in the mouse. *Bone.* 20(1):27-30, 1997 Jan.
48. Kuiper JW, van Kuijk C, Grashuis JL, Ederveen AGH, Schutte HE. Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro. *Osteoporosis International.* 6(1):25-30, 1996.
49. Most W, Schot L, Ederveen A, van der Wee-Pals L, Papapoulos S, Lowik C. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. *Journal of Bone & Mineral Research.* 10(10):1523-30, 1995 Oct.
50. Sloopweg MC, Ederveen AGH, Schot LP, Schoonen WG, Kloosterboer HJ. Oestrogen and progestogen synergistically stimulate human and rat osteoblast proliferation. *Journal of Endocrinology.* 133(2):R5-8, 1992 May.
51. Ederveen AGH, Van Emst-De Vries SE, Burgers LH, De Pont JJ. Purification and characterization of rabbit pancreas protein kinase C. *Pancreas.* 7(1):34-44, 1992.
52. Ederveen AGH, van Emst-de Vries SE, de Pont JJ, Willems PH. Effects of phorbol ester and cholecystokinin on the intracellular distribution of protein kinase C in rabbit pancreatic acini. *European Journal of Biochemistry.* 195(3):679-83, 1991 Feb.
53. Ederveen AGH, Van Emst-De Vries SE, de Pont JJ, Willems PH. Dissimilar effects of the protein kinase C inhibitors, staurosporine and H₇, on cholecystokinin-induced enzyme secretion from rabbit pancreatic

- acini. *European Journal of Biochemistry*. 193(1):291_5, 1990 Oct.
54. Ederveen AGH. van Emst_de Vries SE. De Pont JJ. Willems PH. The diacylglycerol kinase inhibitor, R59022, potentiates cholecystokinin_induced enzyme secretion from rabbit pancreatic acini. *European Journal of Biochemistry*. 188(2):333_8, 1990 Mar.
55. Ederveen AGH. van der Leest JV. van Emst_de Vries SE. de Pont JJ. Phosphorylation of low molecular mass cytosolic proteins by protein kinase C and protein kinase A in the rabbit exocrine pancreas. *European Journal of Biochemistry*. 185(2):461_8, 1989 Nov.
56. Jenks BG. Ederveen AG. Feyen JH. van Overbeeke AP. The functional significance of glycosylation of pro_opiomelanocortin in melanotrophs of the mouse pituitary gland. *Journal of Endocrinology*. 107(3):365_74, 1985 Dec.
57. Peters WH. Ederveen AG. Salden MH. de Pont JJ. Bonting SL. Lack of immunological cross reactivity between the transport enzymes (Na+ + K+)_ATPase and (K+ + H+)_ATPase. *Journal of Bioenergetics & Biomembranes*. 16(3):223_32, 1984 Jun.

Projects

Patents :

1. "15beta_Substituted Steroids Having Selective Estrogenic Activity" HJ Loozen, AGH Ederveen, FA Dijcks. PCT Int Appl No EP 2005/054368, Int Appl No. WO 2006/027347 (16_03_06); priority date 08_09_2004
2. "Substituted 16,17_Annellated Steroid Compounds For Use In Women's Healthcare" FA Dijcks, AGH Ederveen, HJ Loozen. PCT Int. Appl. No EP 2010/058042; Int Appl No. WO 2010/142705 (16_12_2010); priority date 08_06_2010

Memberships

Other Relevant Information